204 related articles for article (PubMed ID: 28899685)
1. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.
Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W
J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685
[TBL] [Abstract][Full Text] [Related]
2. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
[TBL] [Abstract][Full Text] [Related]
3. MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways.
Tang R; Xu X; Yang W; Yu W; Hou S; Xuan Y; Tang Z; Zhao S; Chen Y; Xiao X; Huang W; Guo W; Li M; Deng W
Cancer Lett; 2016 Apr; 373(1):77-87. PubMed ID: 26797421
[TBL] [Abstract][Full Text] [Related]
4. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
[TBL] [Abstract][Full Text] [Related]
5. BET inhibitor suppresses melanoma progression
Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
[No Abstract] [Full Text] [Related]
6. Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
Wang J; Zou K; Feng X; Chen M; Li C; Tang R; Xuan Y; Luo M; Chen W; Qiu H; Qin G; Li Y; Zhang C; Xiao B; Kang L; Kang T; Huang W; Yu X; Wu X; Deng W
Mol Cancer; 2017 Oct; 16(1):158. PubMed ID: 29025423
[TBL] [Abstract][Full Text] [Related]
7. miR-579-3p controls melanoma progression and resistance to target therapy.
Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
[TBL] [Abstract][Full Text] [Related]
8. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK
Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159
[TBL] [Abstract][Full Text] [Related]
9. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.
Zhang C; Smalley I; Emmons MF; Sharma R; Izumi V; Messina J; Koomen JM; Pasquale EB; Forsyth PA; Smalley KSM
J Invest Dermatol; 2021 Apr; 141(4):840-851.e4. PubMed ID: 32890629
[TBL] [Abstract][Full Text] [Related]
10. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
11. Cleavage and polyadenylation specific factor 4 targets NF-κB/cyclooxygenase-2 signaling to promote lung cancer growth and progression.
Yi C; Wang Y; Zhang C; Xuan Y; Zhao S; Liu T; Li W; Liao Y; Feng X; Hao J; Gao Y; Yu W; Chen Y; Zhang C; Guo W; Tang B; Deng W
Cancer Lett; 2016 Oct; 381(1):1-13. PubMed ID: 27450326
[TBL] [Abstract][Full Text] [Related]
12. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.
Talebi A; Dehairs J; Rambow F; Rogiers A; Nittner D; Derua R; Vanderhoydonc F; Duarte JAG; Bosisio F; Van den Eynde K; Nys K; Pérez MV; Agostinis P; Waelkens E; Van den Oord J; Fendt SM; Marine JC; Swinnen JV
Nat Commun; 2018 Jun; 9(1):2500. PubMed ID: 29950559
[TBL] [Abstract][Full Text] [Related]
13. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
14. Melatonin enhances the anti-tumor effect of fisetin by inhibiting COX-2/iNOS and NF-κB/p300 signaling pathways.
Yi C; Zhang Y; Yu Z; Xiao Y; Wang J; Qiu H; Yu W; Tang R; Yuan Y; Guo W; Deng W
PLoS One; 2014; 9(7):e99943. PubMed ID: 25000190
[TBL] [Abstract][Full Text] [Related]
15. TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling.
Che Y; Li Y; Zheng F; Zou K; Li Z; Chen M; Hu S; Tian C; Yu W; Guo W; Luo M; Deng W; Zou L
Cancer Lett; 2019 Jun; 452():1-13. PubMed ID: 30905820
[TBL] [Abstract][Full Text] [Related]
16. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
17. E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma.
Liu X; Mi J; Qin H; Li Z; Chai J; Li M; Wu J; Xu J
J Invest Dermatol; 2020 Jun; 140(6):1295-1299.e1. PubMed ID: 31705876
[No Abstract] [Full Text] [Related]
18. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
19. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
[TBL] [Abstract][Full Text] [Related]
20. Regulation of eIF2α by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance.
Avitan-Hersh E; Feng Y; Oknin Vaisman A; Abu Ahmad Y; Zohar Y; Zhang T; Lee JS; Lazar I; Sheikh Khalil S; Feiler Y; Kluger H; Kahana C; Brown K; Ruppin E; Ronai ZA; Orian A
J Invest Dermatol; 2020 Dec; 140(12):2466-2477. PubMed ID: 32360601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
